Todas as matérias desta seção, das mais recentes às mais antigas — página 159 de 371.
GSK (NYSE:GSK) has entered into a definitive agreement to acquire Nuvalent (NASDAQ:NUVL) for $10.6 billion in cash, marking a substantial expansion of the British drugmaker's oncology franchise through the purchase of three targeted lung cancer therapies.
Vertical Aerospace (NYSE:EVTL) completed the maiden piloted flight of its newest full-scale prototype aircraft, initiating an expanded flight testing campaign ahead of a major design milestone.
Novanta (NASDAQ:NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a developer and manufacturer of specialized minimally invasive surgical consumables, for an upfront cash consideration of $1.2 billion.
Powerlaw (NASDAQ:PWRL) reported a sequential increase in its monthly net asset value, driven by positive valuation updates across its investment portfolio as of the end of May.
Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration has approved its Biologics License Application for TIVDAK, an injectable therapeutic targeting adult patients with recurrent or metastatic cervical cancer.
Oculis Holding (NASDAQ:OCS) announced it has randomized the first patient in its PREDICT-1 clinical trial, marking the launch of the first genotype-based registrational study aimed at treating dry eye disease.
Zepp Health (NYSE:ZEPP) reported a 33.8% increase in first-quarter revenue for fiscal year 2026, driven by robust momentum from its updated premium hardware portfolio during what is traditionally a softer seasonal cycle for consumer electronics.
Baidu (NASDAQ:BIDU) confirmed that the U.S. Department of Defense has included the company on its updated list of "Chinese military companies," a classification the internet search and artificial intelligence giant quickly pushed back against as entirely unjustified.
NIO (NYSE:NIO) confirmed that the U.S. Department of Defense has added the company to its updated list of "Chinese military companies," prompting a swift pushback from the electric vehicle manufacturer as it prepares to contest the designation.
PureTech Health reported that its founded entity, Seaport Therapeutics (NASDAQ:SPTX), achieved positive clinical results from the multiple-ascending dose portion of its Phase 1 proof-of-concept trial evaluating its lead anti-anxiety candidate, GlyphAgo.
EHang Holdings (NASDAQ:EH) reported a widening net loss for the first quarter of fiscal 2026 as near-term commercial deliveries of its flagship autonomous aircraft slowed.
ASE Technology Holding (NYSE:ASX) reported a sharp acceleration in its monthly sales, driven by strong global momentum for its outsourced semiconductor backend services.
Apple (NASDAQ:AAPL) has launched a new suite of parental safety features explicitly inspired by Australia's world-first social media age ban.
OpenAI announced that it has submitted a draft S-1 registration statement to the US Securities and Exchange Commission.
Shares of Eli Lilly (NYSE:LLY) rose 4% on Monday after the company unveiled highly anticipated clinical data for its next-generation obesity treatment, retatrutide.
Alphabet's Google (NASDAQ:GOOGL) has placed an order with Intel (NASDAQ:INTC) to manufacture more than 3 million of its custom artificial intelligence processors in 2028, according to a report from The Information cited by Reuters.
Amazon.com (NASDAQ:AMZN) has signed a multi-billion-dollar agreement with specialty glass maker Corning (NYSE:GLW) to expand the domestic production of optical fiber and connectivity products used to link modern data centers.
VinFast Auto (NASDAQ:VFS) reported a 41.7% increase in first-quarter revenue, boosted by a sharp rise in electric vehicle deliveries and aggressive international retail expansion.
Optical Cable (NASDAQ:OCC) reported a sharp turnaround in its second-quarter financial results for fiscal year 2026, driven by accelerating top-line growth and a substantial expansion of its product backlog.
Novo Nordisk (NYSE:NVO) announced that prescriptions for the oral version of Wegovy have exceeded 3 million since the product’s U.S. market introduction in January 2026.
Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Firefly Bio for $1 billion in cash.
MetaVia (NASDAQ:MTVA) has reported new data from its cardiometabolic pipeline at the American Diabetes Association’s (ADA) 2026 Scientific Sessions in New Orleans.
Neurocrine Biosciences (NASDAQ:NBIX) has announced new clinician-reported data highlighting the effectiveness of INGREZZA (valbenazine) in treating tardive dyskinesia (TD) among individuals with intellectual and developmental disabilities (IDD).
Galmed Pharmaceuticals (NASDAQ:GLMD) has entered into a definitive agreement to acquire Colospan, a commercial-stage medical device company specializing in gastrointestinal surgery solutions.
